poisar

Stocks · News reference

8-K filing — CAPRICOR THERAPEUTICS, INC. (CAPR)

SEC EDGARAug 13, 2026, 8:07 PMSEC EDGAR

Filed: 2026-08-13 AccNo: 0001104659-26-095908 Size: 343 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
edgar
Observed
Aug 13, 2026, 8:07 PM
Checked
Aug 13, 2026, 8:07 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncAug 26, 2026, 1:45 PMKaplan Fox & Kilsheimer Llp

    Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 for a Leadership Role

    Kaplan Fox & Kilsheimer LLP has filed class action lawsuits against Capricor Therapeutics, Pentair plc, and Bloom Energy Corporation on behalf of investors who suffered losses. The primary case involves Capricor, where the FDA released briefing documents revealing that the company made undisclosed changes to its statistical analysis plan for a drug application, resulting in a 64% stock price drop on July 27, 2026.

    Read original at globenewswire-inc
  2. Globenewswire IncAug 26, 2026, 2:05 AMKahn Swick & Foti, Llc

    Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

    A class action lawsuit has been filed against Capricor Therapeutics for allegedly failing to disclose material information regarding changes to its statistical analysis plan for its lead drug candidate Deramiocel. The FDA found the company made undisclosed modifications to the analysis plan just before data unblinding, which the agency deemed post-hoc and exploratory. Following FDA briefing documents on July 27, 2026, Capricor's stock plummeted 64% to $7.00 per share. Investors who purchased securities between December 17, 2025 and July 26, 2026 can apply to join the lawsuit by September 28, 2026.

    Read original at globenewswire-inc